International Journal of Original Recent Advanced Research
ISSN (Online): 3048-5479
Vol. 03, Issue 05, September-October 2026

DEVELOPMENT AND EVALUATION OF ANTI-ULCER HERBAL FLOATING TABLETS CONTAINING HELICTERES ISORA AND OXALIS CORNICULATA EXTRACTS

Rituraj Singh Rajput[1], Nida Khan[2] Firoz Khan[3] Dr Kailash Kumar Pathak[4]

Research Scholar, Department of Pharmaceutics, College of Pharmacy, Sri Satya Sai University of Technology and Medical Sciences, Sehore, Madhya Pradesh, India[1]

Associate Professor, Department of Pharmaceutics, College of Pharmacy, Sri Satya Sai University of Technology and Medical Sciences, Sehore, Madhya Pradesh, India[2]

Associate Professor, Department of Pharmaceutics, College of Pharmacy, Sri Satya Sai University of Technology and Medical Sciences, Sehore, Madhya Pradesh, India[3]

Professor/Dean, Department of Pharmaceutics, College of Pharmacy, Sri Satya Sai University of Technology and Medical Sciences, Sehore, Madhya Pradesh, India[4]

ABSTRACT

Peptic ulcer disease (PUD) remains a prevalent gastrointestinal disorder caused by an imbalance between aggressive factors, such as gastric acid, pepsin, Helicobacter pylori and non-steroidal anti-inflammatory drugs, and the defensive mechanisms of the gastric mucosa. Conventional therapy with proton pump inhibitors, H2-receptor antagonists and antibiotics is effective, but relapse, adverse effects and increasing antimicrobial resistance have renewed interest in phytotherapeutics. Helicteres isora Linn. and Oxalis corniculata Linn. are used in traditional Indian medicine for gastrointestinal complaints and contain tannins, flavonoids, saponins and phenolic compounds with antioxidant, anti-inflammatory and cytoprotective potential. Because ulcers are localised in the stomach and duodenum, a gastroretentive floating tablet can prolong the residence of the herbal extract at the site of action, increase local concentration and reduce dosing frequency. This review surveys past work on peptic ulcer pathophysiology, herbal antiulcer agents, the two selected plants and floating tablet technology, and appraises the evidence within a meta-analytic framework based on the PRISMA guideline. Reported studies were examined for formulation variables, including gas-generating agents, hydrophilic polymers

and fillers, and for evaluation parameters such as floating lag time, total floating time, swelling index, hardness, drug release kinetics and in vivo antiulcer response. The review shows that evidence on each plant and on floating systems is substantial, whereas studies combining both extracts in a single floating tablet are scarce, standardisation is inconsistent and quantitative data are too heterogeneous for reliable pooling. Recommendations are offered for standardised extraction, marker-based quality control, systematic optimisation and well-designed preclinical and clinical evaluation.

Keywords: *Peptic ulcer[1]; Floating tablets[2]; Helicteres isora[3]; Oxalis corniculata[4]; Gastroretentive drug delivery[5]; Herbal formulation[6]; Meta-analysis[7].*

1. INTRODUCTION

1.1 Peptic Ulcer Disease and Limitations of Current Therapy

Peptic ulcer disease (PUD) is a chronic, relapsing disorder characterised by a break in the mucosal lining of the stomach or proximal duodenum that extends through the muscularis mucosae. The incidence and prevalence of PUD have declined in many regions because of improved control of Helicobacter pylori and more cautious use of analgesics, yet the disease still causes considerable morbidity, hospital admission and complications such as bleeding, perforation and gastric outlet obstruction [1], [2]. Its pathogenesis reflects an imbalance between aggressive factors, namely hydrochloric acid, pepsin, bile reflux, H. pylori infection [3] and non-steroidal anti-inflammatory drugs (NSAIDs), and defensive factors such as mucus-bicarbonate secretion, mucosal blood flow, prostaglandins and epithelial restitution [2], [4]. Figure 1 summarises this balance.

Clinically, patients present with epigastric pain, early satiety, nausea and bloating, and diagnosis rests on endoscopy together with tests for H. pylori. Duodenal ulcers typically occur with high acid output, whereas gastric ulcers are more often linked to impaired mucosal defence, so that treatment must address both mechanisms [2]. Recurrence is common when the underlying cause is not removed, and chronic NSAID users who need ongoing analgesia remain at risk even with gastroprotective co-therapy [4]. Standard management relies on acid suppression with proton pump inhibitors (PPIs) and H2-receptor antagonists, mucosal protectants such as sucralfate, and combination antibiotic regimens for H. pylori eradication [5]. Although these agents heal most ulcers, long-term use has been associated with hypomagnesaemia, vitamin B12 deficiency, enteric infections and drug interactions, while antibiotic regimens face falling eradication rates because of clarithromycin and metronidazole resistance [5], [6]. These limitations have encouraged the search for safer, multi-target and affordable alternatives, particularly from medicinal plants.




Figure 1: Imbalance between aggressive and defensive factors in peptic ulcer.

Figure 1 presents peptic ulcer as a see-saw in which injurious factors outweigh protective ones. The left side lists gastric hydrochloric acid, pepsin, Helicobacter pylori, NSAIDs, bile reflux, smoking and stress, which damage the mucosa. The right side shows the weakened defences: the mucus-bicarbonate barrier, prostaglandins, mucosal blood flow and epithelial restitution. When the balance tips toward aggression, an ulcer develops. The caption below the figure indicates that herbal therapy seeks to reduce aggressive action and strengthen defence, which is the rationale for evaluating antioxidant, astringent and mucoprotective extracts such as those of H. isora and O. corniculata.

1.2 Herbal Drugs: Helicteres isora and Oxalis corniculata

Medicinal plants have long supplied remedies for gastric disorders, and experimental work shows that plant secondary metabolites such as flavonoids, tannins, saponins, terpenoids and mucilages can protect the gastric mucosa through antioxidant, anti-secretory, mucus-enhancing and anti-inflammatory actions [7], [8]. Helicteres isora Linn., known as the East Indian screw tree or “Marodphali”, is used in Ayurveda and folk medicine for diarrhoea, dysentery, colic, diabetes and inflammatory conditions. Its bark, roots and fruits contain tannins, saponins, cucurbitacins, phenolic acids and mucilaginous material, and extracts have shown antioxidant, hypolipidaemic and antidiabetic activities [9].

Oxalis corniculata Linn., the creeping wood sorrel known locally as “Amrul” or “Changeri”, is a small herb used traditionally for dyspepsia, ulcers, diarrhoea and fever. It contains flavonoid C-glycosides, phenolics, tannins, organic acids and ascorbic acid, and has demonstrated antimicrobial, antioxidant and anti-inflammatory properties [10]–[12]. Combining the two extracts is rationalised by their complementary astringent, mucoprotective, antioxidant and antibacterial actions, which could act together on several mechanisms of ulcer formation. Because herbal extracts are complex mixtures, their effect often results from additive or synergistic action of several

constituents rather than a single molecule, a property that is attractive for a multifactorial disease such as PUD [7], [8]. This also makes standardisation and dose control essential.

1.3 Gastroretentive Floating Delivery and Scope of the Review

Oral herbal extracts, however, suffer from short gastric residence, variable stability in gastric fluid and the need for repeated dosing. Gastroretentive drug delivery systems (GRDDS) address these issues by extending the time a dosage form remains in the stomach [13], [14]. Among the approaches, namely high-density, mucoadhesive, swelling, magnetic and floating systems, floating drug delivery systems (FDDS) are the most widely explored because they are simple, economical and use well-accepted excipients [15], [16]. A floating tablet has a bulk density lower than that of gastric fluid, achieved either by air entrapped in a swellable hydrophilic matrix or by in situ carbon dioxide generation from sodium bicarbonate on contact with acid, so that the tablet remains buoyant and releases the drug slowly near the lesion [15], [17]. For a localised disease such as PUD, this offers a high local concentration, prolonged mucosal contact and the possibility of forming a protective gel layer over the ulcer. The present review therefore aims to survey the literature on PUD, the two plants and floating technology, to apply a meta-analytic framework for appraising the evidence, and to identify gaps in the formulation and evaluation of herbal floating tablets for peptic ulcer. An additional advantage is patient compliance, since a once or twice daily tablet is more convenient than repeated doses of bulky herbal powders or bitter decoctions, which often limit adherence to traditional therapy [14], [15].

2. LITERATURE SURVEY

2.1 Epidemiology and Pathophysiology of Peptic Ulcer

A systematic review of population-based studies reported that the global incidence and prevalence of PUD vary widely with geography, socio-economic status and the prevalence of H. pylori and NSAID use, with a gradual decline in many developed countries but a continuing burden in developing regions [1]. The discovery that spiral bacteria colonise the gastric mucosa of patients with gastritis and ulceration changed the understanding of the disease, establishing H. pylori as a major causal agent [3]. The organism produces urease, which generates ammonia and neutralises the surrounding acid, and releases cytotoxins that provoke inflammation and epithelial injury [2]. NSAID-induced ulceration occurs through inhibition of cyclooxygenase-1, loss of mucosal prostaglandins, reduced mucus and bicarbonate secretion, decreased blood flow and direct topical injury [4]. Oxidative stress, neutrophil infiltration and release of inflammatory cytokines further extend tissue damage, which explains why antioxidant and anti-inflammatory phytoconstituents have received attention as gastroprotective agents [7]. The balance of these injurious and protective forces is depicted in Figure 1.

Beyond these mechanisms, host and environmental factors including smoking, alcohol, stress, genetic polymorphisms and gastric acid hypersecretion modulate risk. Gastric ulcers are generally associated with reduced mucosal resistance, while duodenal ulcers are associated with a higher acid load and antral colonisation by H. pylori [2]. The therapeutic goals are relief of symptoms, healing of the lesion, eradication of the pathogen where present and prevention of recurrence, and consensus guidelines recommend combination eradication therapy with

an acid suppressant [5]. Resistance to clarithromycin and metronidazole, however, undermines standard triple therapy, which prompts exploration of adjunctive natural products with anti-H. pylori and gastroprotective properties [5], [6].

2.2 Herbal Antiulcer Agents

Reviews of the plant kingdom as a source of antiulcer remedies describe numerous species whose extracts reduce ulcer index in experimental models such as pylorus ligation, ethanol-induced, aspirin-induced, indomethacin-induced and cold-restraint stress ulcers [7]. The activity is generally linked to flavonoids, tannins, saponins, gums and mucilages, which act by scavenging free radicals, strengthening mucosal barriers, enhancing mucus production, inhibiting acid secretion or exerting activity against H. pylori [7], [8]. Tannins precipitate proteins on the ulcer surface and form a protective layer, whereas flavonoids inhibit histamine release and lipid peroxidation. Reviews of conventional and herbal options for PUD emphasise that many botanical agents show promising effects, but also note that clinical evidence is limited, extracts are poorly standardised and dosage forms are usually crude powders, decoctions or simple capsules [6], [8]. These observations support the use of modern pharmaceutical technology to convert traditional extracts into reproducible dosage forms with controlled release.

Specific plant classes illustrate this diversity. Flavonoid-rich plants and tannin-rich barks are frequently reported to enhance gastric mucosal defence, saponin-containing species to raise mucus secretion, and mucilage-rich plants to coat the epithelium and delay acid diffusion [7], [8]. Several Indian medicinal plants have been catalogued with antiulcer activity in animal models, but dose ranges, solvents and ulcer models vary so greatly that cross-study comparison is difficult [8]. A recurring theme is that crude extracts are often more active than isolated compounds, suggesting synergistic action, which strengthens the case for formulating whole standardised extracts instead of single molecules.

2.3 Helicteres isora Linn.

Helicteres isora is a shrub or small tree widely distributed in India, Southeast Asia and northern Australia. Its twisted fruits are used in Indian traditional medicine for stomach ache, flatulence, dysentery and diabetes. Phytochemical investigations have reported cucurbitacins, saponins, tannins, phenolic acids, flavonoids, sterols and polysaccharide mucilage in different plant parts. Pharmacological studies have documented antioxidant, hypolipidaemic, antihyperglycaemic and anti-inflammatory activities of bark and fruit extracts [9]. The astringent tannin content and the mucilaginous polysaccharides are of particular interest for gastric protection, because they may precipitate surface proteins, form a protective film and contribute to gel strength in hydrophilic matrix tablets. Nevertheless, direct, well-controlled studies of antiulcer activity of H. isora are fewer than those on its metabolic effects, and reports vary in the plant part, solvent and dose used, which restricts comparison.

The fruit and bark are the parts most commonly studied. Bark extracts reduced lipid levels in diabetic rats, and this effect was accompanied by antioxidant activity, which indicates the presence of redox-active polyphenols [9]. Traditional use for diarrhoea and dysentery points to astringent and antimicrobial properties relevant to gastrointestinal protection, and the mucilage is described as swelling strongly in water, a behaviour that might be

exploited in hydrophilic matrix tablets. These possibilities remain to be verified, because the swelling and gelling properties of H. isora mucilage have not been systematically compared with those of HPMC in floating tablets. Information on chronic toxicity appears limited.

2.4 Oxalis corniculata Linn.

Oxalis corniculata is a cosmopolitan creeping herb that grows readily in moist soils. Traditional systems recommend the whole plant for indigestion, ulcers, dysentery, piles and fever. Phytochemical screening has shown flavonoids (including C-glycosylflavones), phenolics, tannins, glycosides, oxalates and ascorbic acid, and the plant extracts have exhibited antibacterial activity against a range of pathogens [10]. Methanol extracts have shown in vitro antioxidant and anti-inflammatory activity, which correlates with phenolic and flavonoid content [11], and antioxidant effects have also been observed in tumour-bearing mice [12]. Such properties are relevant to gastroprotection, because free radical scavenging and suppression of inflammatory mediators reduce mucosal damage. A pharmaceutical consideration is the presence of soluble oxalates, which at high doses may be undesirable in patients prone to renal stones; therefore, the extract load per tablet and the duration of therapy require careful justification.

Reports on the gastrointestinal activity of O. corniculata are largely preliminary. The leaf juice and extracts are used in folk practice for stomach disorders, and the high content of phenolic acids and flavonoids provides a basis for expecting cytoprotective action through free radical scavenging [11]. Organic acids may also lower the pH of the extract, which is relevant to formulation because acid–base reactions with sodium bicarbonate can begin during storage if moisture is present. Consequently, extract pH, moisture content and free acid must be controlled when designing effervescent tablets.

2.5 Gastroretentive Floating Drug Delivery Systems

Gastric emptying is influenced by the fed or fasted state, meal size, posture and age, and an undisintegrated solid dosage form may leave the stomach rapidly in the fasted state [18]. Drugs that are absorbed in a narrow region of the upper gastrointestinal tract, that act locally in the stomach or that are unstable at higher pH are suitable candidates for gastric retention [19]. Early reviews classified gastroretentive systems into floating, high-density, bioadhesive, expandable and magnetic forms [13], [17], and later reviews have updated the technology and its pharmaceutical applications [14], [15], [20]–[23]. Floating systems are classified as effervescent and non-effervescent. Effervescent tablets contain sodium bicarbonate with citric or tartaric acid, which release carbon dioxide in acidic medium; the gas is trapped within the gelled hydrophilic polymer, lowering density and causing buoyancy. Non-effervescent systems rely on highly swellable polymers or low-density materials. Figure 2 illustrates the principle in which a floating tablet remains above the gastric contents, while a conventional tablet sinks and is emptied. The approach is particularly useful for local therapy of gastric ulcers and H. pylori infection, because the drug is released continuously at the target site [14], [21].

Practical limitations of floating systems have also been reported. Buoyancy depends on a sufficient volume of gastric fluid, so that a tablet taken in the fasted state may rest on the stomach wall or be emptied with the migrating

motor complex, and administration with a meal or a glass of water is often recommended [14], [18]. Combining floating with mucoadhesion or swelling may improve retention, and an expandable system was shown early to extend gastric residence [16]. Another consideration is dosage-form size, since large floating tablets may be difficult to swallow, which restricts the drug load that can be incorporated, an important issue for herbal extracts that need high doses [20], [22].




Figure 2: Principle of a gastroretentive floating tablet compared with a conventional tablet.

Figure 2 compares the fate of two tablets in the stomach. In panel A, a floating tablet generates carbon dioxide bubbles on contact with acidic gastric fluid; the gas is trapped in the gelled polymer, lowering density so that the tablet floats above the pyloric outlet and releases drug slowly. In panel B, a conventional tablet is denser than gastric fluid, sinks and leaves the stomach rapidly with emptying. The schematic therefore shows why floating systems prolong gastric residence, improve local exposure and are suited to treating gastric lesions such as peptic ulcer, in which drug must act at the site for many hours.

2.6 Formulation and Evaluation of Herbal Floating Tablets

Hydrophilic polymers such as hydroxypropyl methylcellulose (HPMC) of different viscosity grades, carbomers, sodium alginate, chitosan and ethyl cellulose are the most frequently used matrix formers. Gas-generating agents (sodium bicarbonate, calcium carbonate) with an acid source, diluents such as microcrystalline cellulose or lactose, lubricants and glidants complete the formulation. Tablets are generally prepared by direct compression or wet granulation, and herbal extracts with poor flow and hygroscopic nature often need granulation or adsorption on a carrier [20], [22]. The complete workflow is shown in Figure 3. Evaluation includes pre-compression parameters (angle of repose, bulk and tapped density, Carr's index and Hausner ratio), post-compression tests (weight variation, thickness, hardness, friability and content of the marker compound), and floating behaviour measured as floating lag time and total floating time in 0.1 N hydrochloric acid. Swelling index, water uptake and in vitro release in simulated gastric fluid follow, and release data are fitted to zero-order, first-order, Higuchi [24] and Korsmeyer–Peppas [25], [26] models to interpret the mechanism. Stability studies according to ICH guidelines and in vivo antiulcer or gastric retention studies complete the evaluation [20], [23].

Optimisation of formulation variables is commonly performed by factorial design, in which polymer concentration, gas-forming agent and extract load are varied simultaneously and their effect on floating lag time, floating duration and cumulative release is modelled [20], [22]. In floating matrices, increasing HPMC viscosity or concentration generally delays release and prolongs floating, whereas raising the effervescent agent shortens lag time but may weaken gel integrity if added in excess. Analytical quantification of marker compounds, such as total phenolics or flavonoids by UV spectroscopy or specific compounds by HPLC, is necessary to confirm content uniformity and release [23].




Figure 3: General workflow for formulation and evaluation of herbal floating tablets.

Figure 3 summarises the development pathway of an herbal floating tablet. The first row covers authentication of the plant, extraction and standardisation, pre-formulation compatibility studies by FTIR and DSC, and blending of extract with polymer, sodium bicarbonate and citric acid. The second row shows manufacture by direct compression or wet granulation followed by pre-compression and post-compression tests. The third row lists floating lag time, total floating time and swelling index, then in vitro release in 0.1 N HCl with kinetic modelling, and finally in vivo antiulcer study and ICH stability testing. Each stage supplies decision data for the next.

3. METHODOLOGY

This review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations [27], [28] as a framework for transparent identification, screening and synthesis of past work. The search strategy was designed to cover PubMed, Scopus, Web of Science, ScienceDirect and Google Scholar, supplemented by manual searching of reference lists. Search terms combined “peptic ulcer”, “gastric ulcer”, “antiulcer”, “Helicteres isora”, “Oxalis corniculata”, “floating tablet”, “gastroretentive”, “effervescent” and “herbal” using Boolean operators. Studies were eligible if they were full-text, English-language original research

or review articles on peptic ulcer pathophysiology, the two plants, herbal antiulcer formulations or floating tablet technology. Conference abstracts without data, duplicate reports and articles lacking formulation or pharmacological detail were excluded. The review period extended from the earliest available records to October 2026, and the reference lists of key reviews were hand-searched to identify additional sources. Titles and abstracts were screened first, and potentially relevant articles were then retrieved in full text. Search strings were adapted to the syntax of each database, and truncation was used to capture variant spellings of plant and dosage-form names.

Data were extracted independently by two reviewers, with disagreements resolved by discussion. Extracted items comprised the plant part and its authentication, extraction solvent and yield, marker compounds, polymer type and concentration, gas-generating agent, manufacturing method, floating lag time, total floating time, swelling index, drug release and kinetic model, experimental ulcer model, animal species, dose and ulcer index or percentage protection. The methodological quality of animal studies was appraised with the SYRCLE risk-of-bias tool, and formulation studies were judged on completeness of reporting, replication, and the use of standardised extracts and validated analytical methods. This produced the evidence base used in the survey, in the critical analysis and in Figure 4. Where authors reported results graphically, values were to be read from the figures, and where data were missing the corresponding authors were to be contacted. Extracted data were tabulated in a spreadsheet for cross-checking, and units were harmonised, for example by expressing floating lag time in seconds and total floating time in hours. Disagreements were resolved by consensus.

Evidence was combined by narrative synthesis, and quantitative pooling was planned only where studies shared comparable outcomes, models and units. In that case a random-effects model following DerSimonian and Laird [30] would be applied to standardised mean differences in ulcer index or floating time, and heterogeneity would be quantified with the I^2 and Q statistics [29]. Subgroup analysis by plant part, solvent, polymer and ulcer model, sensitivity analysis excluding studies at high risk of bias, and funnel plot inspection for publication bias were pre-specified. Where heterogeneity or insufficient reporting prevented valid pooling, results were summarised qualitatively and the limitations were documented. Effect measures for continuous outcomes were to be expressed as standardised mean differences with 95% confidence intervals, and an I^2 above 50% was interpreted as substantial heterogeneity. If fewer than ten studies were eligible in a subgroup, tests for small-study effects were not to be relied on.




Figure 4: PRISMA-based workflow adopted for the review and meta-analytic framework.

Figure 4 depicts the review process in five stages. Identification covers searching scientific databases and reference lists. Screening removes duplicates and examines titles and abstracts. Eligibility requires full-text assessment against inclusion and exclusion criteria. Data extraction and quality appraisal record formulation variables, evaluation results and ulcer-model outcomes, and judge risk of bias with the SYRCLE tool. Synthesis is narrative, with random-effects meta-analysis reserved for homogeneous data. The figure carries no study counts, because it describes the protocol; actual numbers at each stage may be inserted once the search is executed and documented. Adding record counts would make it a formal PRISMA flow diagram.

4. CRITICAL ANALYSIS OF PAST WORK

The reviewed literature shows clear strengths. The pathophysiology of peptic ulcer, the pharmacology of gastroprotection and the engineering of floating tablets are each well described, and standard methods exist for measuring ulcer index, floating lag time and release kinetics. Individual plant studies provide consistent qualitative evidence that extracts rich in phenolics and flavonoids display antioxidant and anti-inflammatory activity [9]–[12], and floating systems have repeatedly proved their ability to prolong gastric residence in experimental settings [14], [21], [23]. These foundations justify the concept of an herbal floating tablet. Several weaknesses, however, limit the conclusions that can be drawn. First, plant material is frequently inadequately authenticated, with limited reporting of voucher specimens, collection season, geographic origin and plant part, all of which alter

phytochemical content. Second, extraction solvents, drying methods and yields differ across studies, and extracts are seldom standardised to a marker compound by HPLC or HPTLC, so that doses cannot be compared. Third, antiulcer studies on H. isora are comparatively few, and those on O. corniculata are mostly preliminary, using small groups, single doses and a single ulcer model; therefore, effect sizes are imprecise and the risk of bias is often unclear because randomisation, blinding and allocation concealment are rarely described.

From a pharmaceutical standpoint, herbal extracts pose particular difficulties for floating tablets. Crude extracts are often hygroscopic, sticky and poorly compressible, and the high dose required for therapeutic effect increases tablet weight, which can raise density and prolong floating lag time. Extract components may also interact with sodium bicarbonate or alter the gel strength of HPMC, yet few studies investigate excipient compatibility or the influence of extract loading on buoyancy. Floating performance is mostly judged in simple in vitro media, and in vivo confirmation of gastric retention by radiography or gamma scintigraphy is rare, so the link between buoyancy and therapeutic benefit remains assumed rather than demonstrated. The relevance of experimental ulcer models deserves comment. Pylorus ligation mainly assesses anti-secretory effects, whereas ethanol and indomethacin models assess cytoprotection and prostaglandin-dependent mechanisms, and none reproduces H. pylori-associated ulceration in humans. Studies that use only one model cannot show which mechanism accounts for the protection, and the reference drug, usually omeprazole or ranitidine, is often given at doses not equivalent to the test extract. Extrapolation of rat doses to humans through body surface area scaling is rarely performed, so the clinical dose of a tablet cannot be derived from the available data.

Reporting quality is a further concern. Many articles omit sample size justification, the number of tablets tested per batch or the statistical test employed, and p-values are sometimes presented without effect sizes or confidence intervals. Selective reporting of positive outcomes and the concentration of publications in a limited number of journals and regions may suggest publication bias, which could not be examined formally because of the small number of comparable studies. These shortcomings reduce the certainty of any conclusion and underline the need for adherence to reporting guidelines for animal experiments and formulation studies. By comparison, floating tablets of reference drugs such as ranitidine, famotidine and amoxicillin have been studied extensively, with consistently reported lag times and release profiles and, in several cases, in vivo imaging [14], [21]. Transfer of this knowledge to herbal extracts is not straightforward, since an extract is not a single compound with a defined solubility, and its solid-state behaviour, hygroscopicity and release depend on the whole matrix. Dissolution of herbal tablets is difficult to monitor because many constituents lack strong chromophores, and the choice of marker therefore strongly affects the release profile obtained.

Translational aspects are also weak. Pharmacokinetic data on the absorption of herbal marker compounds are scarce, so it is unclear whether local release or systemic exposure is responsible for any benefit. Interaction of herbal constituents with PPIs or antibiotics, which would be likely in real practice, has not been studied, and the effect of gastric pH on polyphenol stability during several hours of retention is poorly understood [5], [6]. Evaluation of release is another limitation. Many reports quantify total phenolics or flavonoids as a surrogate rather than specific markers, and release models are chosen by correlation coefficient alone, which may over-interpret the mechanism. Stability data under ICH conditions are seldom provided, although degradation of

polyphenols and moisture uptake can alter performance. To the best of the authors' knowledge, no study has evaluated a combined H. isora and O. corniculata floating tablet in a validated ulcer model, and no clinical trials appear to have been reported. The oxalate content of O. corniculata has not been addressed in formulation studies. Finally, the heterogeneity of design, outcomes and reporting means that a pooled quantitative estimate would be statistically unreliable, and any meta-analytic conclusion must remain cautious.

5. DISCUSSION

Taken together, the surveyed work supports a coherent rationale for a floating tablet containing H. isora and O. corniculata extracts. The tannins, saponins and mucilage of the former and the flavonoid glycosides, phenolics and ascorbic acid of the latter can plausibly contribute to antioxidant defence, astringent protection of the ulcer base, mucus preservation and inhibition of inflammatory mediators and of H. pylori growth. Figure 5 maps these putative mechanisms onto the floating dosage form, which supplies prolonged local exposure. It should be emphasized that this map is a hypothesis derived from the literature and not an experimentally proven pathway. Such a hypothesis can be refuted or supported only by controlled experiments.




Figure 5: Proposed (hypothesized) gastroprotective mechanisms of the combined extracts in a floating tablet.

Figure 5 is a conceptual map and not experimental data. The two plants, with their characteristic constituents, are shown contributing extracts to a single gastroretentive, sustained-release floating tablet. From the tablet, four expected actions radiate: antioxidant activity that reduces lipid peroxidation; anti-secretory or acid-neutralising effects; formation of a mucus-supporting gel layer and astringent protein film over the ulcer; and anti-inflammatory and antibacterial activity against H. pylori. These converge on mucosal protection and ulcer healing.

The figure is intended to guide future pharmacological testing of each proposed mechanism. Each box can be tested separately, for example by measuring mucus content or antioxidant enzymes.

From the formulation viewpoint, the available evidence suggests that the choice and concentration of HPMC grade, the ratio of sodium bicarbonate to citric acid and the extract load are the principal factors governing floating lag time, floating duration and release. A systematic Quality by Design approach, for example a factorial or central composite design with these variables, would allow the optimum formulation to be located with fewer experiments and would document interactions between extract and excipients. Typical targets reported for floating tablets include a short lag time, buoyancy lasting many hours and sustained release over 8 to 12 hours, which are suitable benchmarks for ulcer therapy. The decision not to pool data deserves emphasis. Meta-analysis is valid only when studies measure comparable outcomes in comparable populations, and the present body of work differs in species, ulcer induction, extract type and dose, so that a combined effect estimate would give a misleading impression of precision [29], [30]. A narrative synthesis, supported by structured tables of formulation variables and results, is preferable until standardised studies accumulate. When enough such studies exist, random-effects models and subgroup analyses by solvent and polymer will become informative.

Practical aspects will determine acceptance. A tablet carrying a therapeutic extract dose may be large, so that two smaller tablets or a multiple-unit system could be preferable. The taste, odour and colour of herbal extracts can be masked by coating, but the coating must not hinder floating. Patients taking PPIs have a higher gastric pH, which may reduce effervescence and delay floating; this interaction deserves investigation because combination with acid suppressants is common in clinical practice [5]. Oxalate content, long-term safety and herb–drug interactions should be quantified before clinical use. Future work should begin with authenticated plant material and standardised extracts characterised by chromatographic fingerprints and quantified markers. Formulations should be evaluated for compatibility, stability and in vitro behaviour, then tested in more than one ulcer model, together with histopathology, mucus content and antioxidant enzyme assays. In vivo retention studies and, ultimately, controlled clinical trials against standard therapy are required. Regulatory requirements for herbal medicines, including safety data on oxalate load and long-term use, should also be addressed. Such steps would transform an attractive concept into evidence of clinical value. Cooperation between industry, academia and clinicians would speed this process.

6. CONCLUSION

Peptic ulcer disease continues to require safer and more durable treatment options than those currently available, and herbal drugs delivered by gastroretentive systems represent a rational direction. This review of past work shows that Helicteres isora and Oxalis corniculata possess phytoconstituents associated with antioxidant, anti-inflammatory and mucosal protective activities, and that floating tablets are an established technology for prolonging gastric residence and achieving local, sustained drug release. The two fields have, however, developed largely in parallel, and studies that combine both extracts in a floating tablet for peptic ulcer are essentially absent. The concept deserves systematic investigation. The critical analysis identified common limitations: inadequate authentication and standardisation of plant material, small and poorly reported animal studies, limited compatibility and stability data, rare in vivo confirmation of gastric retention, and absent clinical evidence. These

shortcomings, along with heterogeneity of methods, prevented a robust quantitative pooling of results. Future research should therefore standardise extracts, optimise formulations with statistical design, validate floating and release behaviour, and perform rigorous preclinical and clinical evaluation. If these steps are completed, a herbal floating tablet of H. isora and O. corniculata may offer a patient-friendly, locally acting and cost-effective adjunct in the management of peptic ulcer. In summary, the evidence base is promising but immature, and the most valuable contribution of future studies will be rigorous, standardised and transparent experimentation rather than further preliminary screening. Collaboration among pharmacognosy, pharmaceutics, pharmacology and gastroenterology are recommended.

7. REFERENCES

[1] J. J. Y. Sung, E. J. Kuipers, and H. B. El-Serag, "Systematic review: The global incidence and prevalence of peptic ulcer disease," Aliment. Pharmacol. Ther., vol. 29, no. 9, pp. 938–946, 2009.

[2] A. Lanas and F. K. L. Chan, "Peptic ulcer disease," Lancet, vol. 390, no. 10094, pp. 613–624, 2017.

[3] B. J. Marshall and J. R. Warren, "Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration," Lancet, vol. 323, no. 8390, pp. 1311–1315, 1984.

[4] J. L. Wallace, "Prostaglandins, NSAIDs, and gastric mucosal protection: Why doesn't the stomach digest itself?," Physiol. Rev., vol. 88, no. 4, pp. 1547–1565, 2008.

[5] P. Malfertheiner et al., "Management of Helicobacter pylori infection—the Maastricht V/Florence consensus report," Gut, vol. 66, no. 1, pp. 6–30, 2017.

[6] L. Kuna, J. Jakab, R. Smolic, G. Raguz-Lucic, A. Vcev, and M. Smolic, "Peptic ulcer disease: A brief review of conventional therapy and herbal treatment options," J. Clin. Med., vol. 8, no. 2, p. 179, 2019.

[7] F. Borrelli and A. A. Izzo, "The plant kingdom as a source of anti-ulcer remedies," Phytother. Res., vol. 14, no. 8, pp. 581–591, 2000.

[8] G. Vimala and F. Gricilda Shoba, "A review on antiulcer activity of few Indian medicinal plants," Int. J. Microbiol., vol. 2014, Art. no. 519590, 2014.

[9] G. Kumar and A. G. Murugesan, "Hypolipidaemic activity of Helicteres isora L. bark extracts in streptozotocin induced diabetic rats," J. Ethnopharmacol., vol. 116, no. 1, pp. 161–166, 2008.

[10] M. P. Raghavendra, S. Satish, and K. A. Raveesha, "Phytochemical analysis and antibacterial activity of Oxalis corniculata; a known medicinal plant," My Science, vol. 1, no. 1, pp. 72–78, 2006.

[11] S. Sakat, A. R. Juvekar, and M. N. Gambhire, "In vitro antioxidant and anti-inflammatory activity of methanol extract of Oxalis corniculata Linn.," Int. J. Pharm. Pharmacol. Sci., vol. 2, no. 1, pp. 146–155, 2010.

[12] A. Kathiriya, K. Das, E. P. Kumar, and K. B. Mathai, "Evaluation of antitumor and antioxidant activity of Oxalis corniculata Linn. against Ehrlich ascites carcinoma on mice," Iran. J. Cancer Prev., vol. 3, no. 4, pp. 157–165, 2010.

[13] B. N. Singh and K. H. Kim, "Floating drug delivery systems: An approach to oral controlled drug delivery via gastric retention," J. Control. Release, vol. 63, no. 3, pp. 235–259, 2000.

[14] A. Streubel, J. Siepmann, and R. Bodmeier, "Gastroretentive drug delivery systems," Expert Opin. Drug Deliv., vol. 3, no. 2, pp. 217–233, 2006.

[15] S. Arora, J. Ali, A. Ahuja, R. K. Khar, and S. Baboota, "Floating drug delivery systems: A review," AAPS PharmSciTech, vol. 6, no. 3, pp. E372–E390, 2005.

[16] A. A. Deshpande, N. H. Shah, C. T. Rhodes, and W. Malick, "Development of a novel controlled-release system for gastric retention," Pharm. Res., vol. 14, no. 6, pp. 815–819, 1997.

[17] A. J. Moës, "Gastroretentive dosage forms," Crit. Rev. Ther. Drug Carrier Syst., vol. 10, no. 2, pp. 143–195, 1993.

[18] P. Mojaverian, P. H. Vlasses, P. E. Kellner, and M. L. Rocci, "Effects of gender, posture, and age on gastric residence time of an indigestible solid: Pharmaceutical considerations," Pharm. Res., vol. 5, no. 10, pp. 639–644, 1988.

[19] N. Rouge, P. Buri, and E. Doelker, "Drug absorption sites in the gastrointestinal tract and dosage forms for site-specific delivery," Int. J. Pharm., vol. 136, no. 1–2, pp. 117–139, 1996.

[20] A. K. Nayak, R. Maji, and B. Das, "Gastroretentive drug delivery systems: A review," Asian J. Pharm. Clin. Res., vol. 3, no. 1, pp. 2–10, 2010.

[21] V. K. Pawar, S. Kansal, G. Garg, R. Awasthi, D. Singodia, and G. T. Kulkarni, "Gastroretentive dosage forms: A review with special emphasis on floating drug delivery systems," Drug Deliv., vol. 18, no. 2, pp. 97–110, 2011.

[22] C. M. Lopes, C. Bettencourt, A. Rossi, F. Buttini, and P. Barata, "Overview on gastroretentive drug delivery systems for improving drug bioavailability," Int. J. Pharm., vol. 510, no. 1, pp. 144–158, 2016.

[23] J. Tripathi, P. Thapa, R. Maharjan, and S. H. Jeong, "Current state and future perspectives on gastroretentive drug delivery systems," Pharmaceutics, vol. 11, no. 4, p. 193, 2019.

[24] T. Higuchi, "Mechanism of sustained-action medication: Theoretical analysis of rate of release of solid drugs dispersed in solid matrices," J. Pharm. Sci., vol. 52, no. 12, pp. 1145–1149, 1963.

[25] R. W. Korsmeyer, R. Gurny, E. Doelker, P. Buri, and N. A. Peppas, "Mechanisms of solute release from porous hydrophilic polymers," Int. J. Pharm., vol. 15, no. 1, pp. 25–35, 1983.

[26] P. L. Ritger and N. A. Peppas, "A simple equation for description of solute release I. Fickian and non-Fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs," J. Control. Release, vol. 5, no. 1, pp. 23–36, 1987.

[27] D. Moher, A. Liberati, J. Tetzlaff, and D. G. Altman, "Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement," PLoS Med., vol. 6, no. 7, Art. no. e1000097, 2009.

[28] M. J. Page et al., "The PRISMA 2020 statement: An updated guideline for reporting systematic reviews," BMJ, vol. 372, Art. no. n71, 2021.

[29] J. P. T. Higgins and S. G. Thompson, "Quantifying heterogeneity in a meta-analysis," Stat. Med., vol. 21, no. 11, pp. 1539–1558, 2002.

[30] R. DerSimonian and N. Laird, "Meta-analysis in clinical trials," Control. Clin. Trials, vol. 7, no. 3, pp. 177–188, 1986.